当前位置: 首页 > 详情页

Ligustilide provides neuroprotection by promoting angiogenesis after cerebral ischemia.

| 导出 | |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University , Beijing, China. [2]BeijingKey Laboratory of Hypoxia Translational Medicine , Beijing, China. [3]Center of Stroke, Beijing Institute for Brain Disorder , Beijing, China. [4]Department of Herbal Formula Science Medicine, Chinese Medicine School, Beijing University of Chinese Medicine , Beijing, China. [5]Department of Neurosurgery, Wayne State University School of Medicine , Detroit, MI, USA.
出处:
ISSN:

摘要:
Following stroke, angiogenic strategy has been proposed to alleviate ischemia-induced injury by promoting angiogenesis and improving cerebrovascular function in the ischemic regions. Ligustilide (LGSL) is known to have neuroprotection against ischemic stroke-induced injury. But the effect of LGSL on promoting angiogenesis after ischemic stroke is unknown. The purpose of this study was to determine the effects of LGSL on neuroprotection and angiogenesis after stroke. BrdU cell proliferation assay, transwell, wound healing, and tube-formation experiments were performed to evaluate the effects of LGSL on mouse microvascular endothelial cells (bEnd.3). Male adult C57/BL6 mice were subjected to focal transient cerebral ischemia followed by intragastric LGSL administration. Immunostaining was performed to assess angiogenesis. VEGF level was assayed by ELISA. eNOS expression was performed by Western blot. LGSL significantly improved neurological function. LGSL promoted angiogenesis in vitro and in vivo. Neurological improvement conferred by LGSL correlated with increased cerebral vessels number. We also found an increase of VEGF and eNOS activation in mice ischemic hemisphere following LGSL administration. LGSL promoted focal angiogenesis and attenuated ischemia-induced brain injury, suggesting that LGSL is a potential agent that improves angiogenesis and promotes recovery from ischemic stroke.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 临床神经病学 4 区 神经科学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 临床神经病学 4 区 神经科学
JCR分区:
出版当年[2018]版:
Q3 CLINICAL NEUROLOGY Q4 NEUROSCIENCES
最新[2023]版:
Q3 CLINICAL NEUROLOGY Q4 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Institute of Hypoxia Medicine, Xuanwu Hospital, Capital Medical University , Beijing, China. [2]BeijingKey Laboratory of Hypoxia Translational Medicine , Beijing, China. [3]Center of Stroke, Beijing Institute for Brain Disorder , Beijing, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17010 今日访问量:0 总访问量:909 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院